Table 1 Patients and Implantation Characteristics
From: Permanent iodine-125 brachytherapy for patients with progressive or recurrent high-grade gliomas
Characteristics | SI(n = 29) | SRCI(n = 29) | p Valuea |
|---|---|---|---|
Age (yrs) | 0.637 | ||
Median (Range) | 46 (20–73) | 46 (16–70) | |
Sex | 0.588 | ||
Male | 17 (58.6) | 19 (65.5) | |
Female | 12 (41.4) | 10 (34.5) | |
KPS | 22 (75.9) | ||
Median (Range) | 80 (50–80) | 80 (50–90) | 0.401 |
90–100 | 11 (37.9) | 8 (27.6) | |
≤ 80 | 18 (62.1) | 21 (72.4) | |
Extent of Resection | |||
Gross total resection | 29 (100) | 29 (100) | |
Partial resection | 0 (0) | 0 (0) | |
Biopsy | 0 (0) | 0 (0) | |
ERBT dose (Gy) | |||
Median (Range) | / | 60 (34-70Gy) | |
Adjuvant chemotherapy | / | 11 (37.9) | |
Tumor position | |||
Frontal lobe | 6 (20.7) | 11 (37.9) | |
Occipital lobe | 1 (3.5) | 0 (0) | |
Parietal lobe | 4 (13.8) | 0 (0) | |
Temporal lobe | 9 (31.0) | 6 (20.7) | |
multi-lobe | 9 (31.0) | 12 (41.4) | |
Tumor location | |||
Left hemisphere | 16 (55.2) | 13 (44.8) | |
Right hemisphere | 11 (37.9) | 16 (55.1) | |
Both hemisphere | 2 (6.9) | 0 (0) | |
Tumor Diameter | 0.588 | ||
≥ 5 cm | 12 (41.4) | 10 (34.5) | |
< 5 cm | 17 (58.6) | 19 (65.5) | |
Histology | 0.753 | ||
WHO III | 7 (24.1) | 6 (20.7) | |
WHO IV | 22 (75.9) | 23 (79.3) | |
No. of seeds | 0.368 | ||
Median (Range) | 45 (16–150) | 40 (20–98) | |
PD (Gy) | 110 (100–150) | 110 (100–150) | 0.655 |
Symptoms prior to implantation | |||
Headace | 27 (93.1) | 27 (93.1) | > 0.999 |
Nausea | 22 (75.9) | 18 (62.1) | 0.256 |
Vomit | 14 (48.3) | 12 (41.4) | 0.597 |
Vertigo | 6 (20.7) | 9 (31.0) | 0.368 |
Myodynamic | 0.387 | ||
≥ grade 4 | 22 (75.9) | 19 (65.5) | |
< grade 4 | 7 (24.1) | 10 (34.5) | |
Vision | 6 (20.7) | 10 (34.5) | 0.240 |
Hearing | 5 (17.2) | 3 (10.3) | 0.446 |
Aphasia | 6 (20.7) | 4 (13.8) | 0.487 |
Epilepsy | 22 (75.9) | 11 (37.9) | 0.004 |
Sensory | 3 (10.3) | 5 (17.2) | 0.446 |